Pharmacoepidemiological analysis of drug therapy for chronic spontaneous urticaria in the Smolensk region
Авторы
-
Aleksandr V. Vitchuk
molensk State Medical University of the Ministry of Health of the Russian Federation
https://orcid.org/0000-0003-4814-3847
-
Vasilii E. Novikov
Smolensk State Medical University of the Ministry of Health of the Russian Federation
https://orcid.org/0000-0002-0953-7993
-
Svetlana A. Aksenova
molensk State Medical University of the Ministry of Health of the Russian Federation
https://orcid.org/0000-0003-1539-6709
-
Elena V. Pozhilova
Smolensk State Medical University of the Ministry of Health of the Russian Federation
https://orcid.org/0000-0002-7372-7329
-
Elena V. Volkova
Smolensk Regional State Budgetary Healthcare Institution ”Clinical Hospital №1”
https://orcid.org/0009-0003-5301-115X
DOI:
https://doi.org/10.18413/rrpharmacology.12.1109Аннотация
Introduction: Pharmacotherapy for patients with chronic spontaneous urticaria should follow the algorithm presented in the Federal Clinical Guidelines of Russia. Adherence to recommended therapy significantly improves treatment effectiveness and safety. However, routine clinical practice often shows deviations from the therapeutic algorithm, which requires prompt identification and correction. Aim of the study: To conduct a pharmacoepidemiological analysis of chronic spontaneous urticaria treatment in the Smolensk region to improve pharmacotherapy effectiveness and safety.
Materials and Methods: Retrospective analysis of 284 medical records of adult patients with chronic spontaneous urticaria hospitalized at the Smolensk Regional Center of Allergology and Immunology (2014–2024).
Results: At the outpatient stage, 247 patients (87.0%; 95% CI: 83.1–90.9%) used second-generation antihistamines at clinical guideline-permitted dosage, 63 patients (22.2%; 95% CI: 17.4– 27.0%) – first-generation antihistamines, and 111 patients (39.1%; 95% CI: 33.4–44.8%) –systemic glucocorticoids. At the inpatient stage, all 284 patients received second-generation antihistamines, 12 (4.2%; 95% CI: 1.9–6.6%) first-generation antihistamines, and 35 patients (12.3%; 95% CI: 8.5–16.1%) systemic glucocorticoids. During the first hospitalization, 18 patients with chronic spontaneous urticaria received an initiating dose of omalizumab. Off-guideline drugs (sodium thiosulfate, ketotifen, calcium gluconate, histaglobulin) were used in isolated cases.
Conclusion: The analysis revealed good adherence to the therapeutic algorithm for chronic spontaneous urticaria treatment in the Smolensk region. Deviations from the recommended treatment algorithm (first-generation antihistamines and prolonged systemic glucocorticoids) identified during the study require individual analysis and further correction to optimize patient care.
Графическая аннотация
Ключевые слова:
антигистаминные, хроническая спонтанная крапивница, омализумаб, фармакотерапия, системные глюкокортикоидыБиблиографические ссылки
Bernstein JA, Winders TA, McCarthy J, Saraswat P, Chapman-Rothe N, Raftery T, Weller K (2025) Urticaria voices: Real-world treatment patterns and outcomes in chronic spontaneous urticaria. Dermatology and Therapy (Heidelberg) 15(8): 2201–2215. https://doi:10.1007/s13555-025-01461-8 [PubMed] [PMC]
Chu AWL, Oykhman P, Chu X, Rayner DG, Bhangal S, Dam A, Xu J, Sheikh J, Trayes KP, Frazier WT, Lang DM, Beck LA, Mathur SK, Waserman S, Thabane L, Asiniwasis RN, Runyon L, Moellman J, Oliver ET, Chan J, Cole EF, Baker DR, Khan DA, Ben-Shoshan M, Wheeler KE, Eftekhari S, Gardner DD, Winders T, Flindall M, Tattrie J, Bernstein JA, Saini SS, Chu DK (2025) Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis. The Journal of Allergy and Clinical Immunology 156(4): 1008–1023. https://doi:10.1016/j.jaci.2025.06.004 [PubMed]
Clinical guidelines – Urticaria – 2023-2024-2025 (07/19/2023) – Approved by the Ministry of Health of the Russian Federation. https://cr.minzdrav.gov.ru/preview-cr/264_2
Iriarte Sotés P, Armisén M, Usero-Bárcena T, Rodriguez Fernández A, Otero Rivas MM, Gonzalez MT, Meijide Calderón A, Veleiro B; Urtigal, the Galician Group of Interest in Urticaria (2020) Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: A systematic review of the literature. Journal of Investigational Allergology & Clinical Immunology 31(4): 282–291. https://doi:10.18176/jiaci.0649 [PubMed]
Kocatürk E, Chu DK, Türk M, Röckmann H, Van Doorn M, Nochaiwong S, Zuberbier T (2025) Management of chronic spontaneous urticaria made practical: What every clinician should know. The Journal of Allergy and Clinical Immunology. In practice 13(9): 2252–2269. https://doi:10.1016/j.jaip.2025.07.021 [PubMed]
Kolkhir P, Fok JS, Kocatürk E, Li PH, Okas TL, Marcelino J, Metz M (2025) Update on the treatment of chronic spontaneous urticaria. Drugs 85(4): 475–486. https://doi:10.1007/s40265-025-02170-4 [PubMed] [PMC]
Ledford D, Broder MS, Antonova E, Omachi TA, Chang E, Luskin A (2016) Corticosteroid-related toxicity in patients with chronic idiopathic urticaria / chronic spontaneous urticaria. Allergy and Asthma Proceedings 37(6): 458–465. https://doi:10.2500/aap.2016.37.3999[PubMed]
Maurer M, Costa C, Gimenez Arnau A, Guillet G, Labrador-Horrillo M, Lapeere H, Meshkova R, Savic S, Chapman-Rothe N (2020) Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clinical and Experimental Allergy 50(10): 1166–1175. https://doi:10.1111/cea.13716 [PubMed]
Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, Gomez M, Gonzalez-Diaz SN, Martin B, Morais-Almeida M, Ortega Martell JA (2021) The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. The World Allergy Organization Journal 14(6): 100533. https://doi:10.1016/j.waojou.2021.100533 [PubMed] [PMC]
Soong W, Patil D, Pivneva I, Signorovitch J, Wells MA, Balp MM, Kuruvilla M (2023) Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria. The World Allergy Organization Journal 16(12): 100843. https://doi:10.1016/j.waojou.2023.100843 [PubMed] [PMC]
Warp PV, Giménez-Arnau AM, Kim BS, Netchiporouk E, Metz M, Yosipovitch G, Elman SA (2026) Chronic Urticaria Part I: Clinical overview and molecular basis. Journal of the American Academy of Dermatology S0190-9622(25): 03505-4. https://doi:10.1016/j.jaad.2025.12.106 [PubMed]
Weller K, Winders TA, McCarthy J, Saraswat P, Chapman-Rothe N, Raftery T, Bernstein JA (2025) The Urticaria voices study: Physicians' perspectives on the real-world patient burden, treatments, and outcomes in chronic spontaneous urticaria. Dermatology and Therapy 15(10): 2925–2946. https://doi:10.1007/s13555-025-01498-9 [PubMed] [PMC]
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, Ballmer-Weber B, Bangert C, Ben-Shoshan M, Bernstein JA, Bindslev-Jensen C, Brockow K, Brzoza Z, Chong Neto HJ, Church MK, Criado PR, Danilycheva IV, Dressler C, Ensina LF, Fonacier L, Gaskins M, Gáspár K, Gelincik A, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Grosber M, Hamelmann E, Hébert J, Hide M, Kaplan A, Kapp A, Kessel A, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Lauerma A, Leslie TA, Magerl M, Makris M, Meshkova RY, Metz M, Micallef D, Mortz CG, Nast A, Oude-Elberink H, Pawankar R, Pigatto PD, Ratti Sisa H, Rojo Gutiérrez MI, Saini SS, Schmid-Grendelmeier P, Sekerel BE, Siebenhaar F, Siiskonen H, Soria A, Staubach-Renz P, Stingeni L, Sussman G, Szegedi A, Thomsen SF, Vadasz Z, Vestergaard C, Wedi B, Zhao Z, Maurer M (2022) The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 77(3): 734–766. https://doi:10.1111/all.15090[PubMed]
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO (2014) Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69(7): 868–887. https://doi.org/10.1111/all.12313 [PubMed]
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2026 Vitchuk AV, Novikov VE, Aksenova SA, Pozhilova EV, Volkova EV
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Русский
English
